⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973031 | 1.00 | — | — | |
| SCHEMBL12409742 | 0.81 | — | — | |
| SCHEMBL12107520 | 0.81 | — | — | |
| SCHEMBL12459955 | 0.81 | — | — | |
| SCHEMBL9865753 | 0.81 | — | — | |
| SCHEMBL23158355 | 0.81 | — | — | |
| SCHEMBL14285551 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL30683992 | 0.79 | IRAK4 (0.39) | — | |
| SCHEMBL21274152 | 0.79 | IRAK4 (0.42) | — | |
| SCHEMBL28460243 | 0.79 | CA2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| JP-2007513098-A | — | — | 2007-05-24 | — | — | JP | claimed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | claimed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005054179-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2005-06-16 | — | — | WO | claimed |
| CN-114591223-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| CN-114591223-A | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-109715630-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| EP-3512851-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | Entasis Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | disclosed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054179-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2005-06-16 | — | — | WO | disclosed |